Loading...
XKRX
200780
Market cap27mUSD
Jul 25, Last price  
4,500.00KRW
1D
0.45%
1Q
-8.72%
Jan 2017
-78.69%
IPO
-60.98%
Name

BCWorldPharm Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
0.51
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.92%
Rev. gr., 5y
7.76%
Revenues
74.81b
-0.39%
41,414,969,86245,657,695,80750,207,424,01354,791,756,08451,497,337,12457,030,365,93362,079,356,72472,702,521,72375,110,698,90074,814,338,700
Net income
-4.43b
L
6,326,463,8986,474,768,6838,082,648,5304,992,558,386-1,552,775,587-1,579,980,801-1,843,084,839281,295,1102,633,791,272-4,432,502,590
CFO
4.04b
-63.04%
8,781,652,758243,663,5097,899,693,8285,287,429,89012,109,512,525-5,502,425,522-619,833,3586,883,046,84210,937,646,9204,042,224,510
Dividend
Dec 27, 2023100 KRW/sh

Profile

BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberculosis drugs, anti-emetic, antiviral drugs, antibiotic, anti-malignant tumor drugs, antifungal agent, antihistamines, antidote, and antipyretic/analgesic/anti-inflammatory. BCWORLD PHARM. Co., Ltd. was founded in 1980 and is headquartered in Seongnam-si, South Korea.
URL
https://www.bcwp.co.kr/
IPO date
Dec 15, 2014
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
74,814,339
-0.39%
75,110,699
3.31%
72,702,522
17.11%
Cost of revenue
61,045,874
53,017,206
66,297,469
Unusual Expense (Income)
NOPBT
13,768,465
22,093,493
6,405,053
NOPBT Margin
18.40%
29.41%
8.81%
Operating Taxes
550,120
(1,686,176)
(1,582,690)
Tax Rate
4.00%
NOPAT
13,218,344
23,779,669
7,987,742
Net income
(4,432,503)
-268.29%
2,633,791
836.31%
281,295
-115.26%
Dividends
(542,732)
(542,732)
(853,856)
Dividend yield
1.25%
1.00%
1.18%
Proceeds from repurchase of equity
32,950,791
BB yield
-45.65%
Debt
Debt current
74,516,127
79,845,663
72,930,139
Long-term debt
15,215,923
12,616,576
21,324,771
Deferred revenue
Other long-term liabilities
(380)
370
154,871
Net debt
81,366,728
79,512,385
84,834,859
Cash flow
Cash from operating activities
4,042,225
10,937,647
6,883,047
CAPEX
(2,397,843)
(2,576,918)
(6,438,602)
Cash from investing activities
(1,138,533)
(3,764,316)
(6,677,590)
Cash from financing activities
(4,522,888)
(4,248,191)
1,072,557
FCF
16,417,557
27,889,505
8,005,129
Balance
Cash
7,911,412
11,165,599
8,057,941
Long term investments
453,910
1,784,255
1,362,110
Excess cash
4,624,605
9,194,319
5,784,925
Stockholders' equity
42,641,306
46,500,386
44,150,808
Invested Capital
160,339,838
162,515,682
165,937,552
ROIC
8.19%
14.48%
4.80%
ROCE
8.35%
12.87%
3.73%
EV
Common stock shares outstanding
9,302
8,439
8,522
Price
4,670.00
-27.71%
6,460.00
-23.73%
8,470.00
-46.56%
Market cap
43,439,224
-20.31%
54,513,130
-24.48%
72,182,924
-46.66%
EV
124,148,574
132,251,983
154,985,733
EBITDA
21,462,487
29,563,023
13,668,085
EV/EBITDA
5.78
4.47
11.34
Interest
4,760,466
5,234,000
3,791,585
Interest/NOPBT
34.58%
23.69%
59.20%